May 2013 Issue

Commentary

Hemoglobin Levels Fall, Transfusions On the Rise

Expert Q&A

New Prostate Center to Focus on Improving Everything from Diagnosis to Treatment: An Interview with Ashutosh K. Tewari, MB, BS

Subscribe
Archive

May 2013

Subscribe

Editorial Board	Login \| Register

Nephrology

Latest Nephrology news and features

Urology

Latest Urology news and features

Get the App

Download our free app for iOS or Android

Tweet

December 01, 2011

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Sponsors and Collaborators
Allergan

Contact
Allergan Inc.
clinicaltrials@allergan.com

ClinicalTrials.gov Identifier
NCT00439140

Similar Articles

Next Article in Overactive Bladder Clinical Trials

A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder

RUN Articles

More in Overactive Bladder Clinical Trials

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for ...

A look at the following clinical trial: Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug.

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat ...

A look at the following clinical trial: Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder.

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

A look at the following clinical trial: Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease.